Business, energy, technology, markets and global industry news from Business News Today

Phase 3 clinical trial

PharmaDeviceNews Phase 3 clinical trial
Representative image: Ophthalmology slit-lamp examination reflecting the unmet treatment need in neuropathic corneal pain as OKYO Pharma advances urcosimod toward the Phase 3 NEPTUNE trial.
Pharma & Biotech

Could OKYO Pharma’s urcosimod finally crack a painful eye disease with no approved therapy?

OKYO Pharma’s urcosimod moves toward Phase 3 as the biotech targets neuropathic corneal pain, a severe ocular condition without approved therapy.

Read More
Representative image: A PET/CT imaging suite illustrates how Pentixapharm’s [68Ga]Ga-PentixaFor Phase 3 PANDA study could reshape primary aldosteronism diagnostics and cardiovascular precision medicine.
Medical Devices & Diagnostics

Why a CXCR4 PET/CT tracer could become Pentixapharm’s most important cardiovascular asset

See why Pentixapharm’s Phase 3 CXCR4 PET/CT push could challenge a stubborn diagnostic bottleneck in primary aldosteronism.

Read More
Representative image of MRI brain scan analysis as Ono Pharmaceutical’s ONO-2808 trial data highlights new research momentum in multiple system atrophy treatment.
Pharma & Biotech

Why Ono’s Phase 2 MSA data may matter beyond one World Parkinson Congress poster

Ono’s ONO-2808 data hints at disease modification in MSA. See why Phase 3 may decide whether the signal becomes a breakthrough.

Read More
Representative image: Vistagen’s fasedienol Phase 3 trial highlights the growing search for rapid, as-needed nasal spray treatments for social anxiety disorder, especially in high-pressure public speaking and performance settings.
Pharma & Biotech

Why PALISADE-4 is a high-stakes test for Vistagen’s nose-to-brain anxiety drug strategy

Social anxiety needs faster options. Vistagen’s fasedienol now faces the Phase 3 test that could make or break its nasal-spray thesis.

Read More
Representative image: Corcept Therapeutics’ dazucorilant survival signal in amyotrophic lateral sclerosis highlights how ALS clinical trials are shifting attention from short-term functional scores to longer-term survival outcomes.
Pharma & Biotech

A failed ALS trial still showed a stunning survival signal. Can Corcept turn it into Phase 3 proof?

A failed ALS endpoint meets a striking survival signal. Corcept now faces the harder test: proving dazucorilant in Phase 3.

Read More
Pharma & Biotech

Scancell’s late-stage push for iSCIB1+ reframes the risk calculus in advanced melanoma trials

FDA clears Scancell’s iSCIB1+ for Phase 3 testing in advanced melanoma. Discover what this means for immunotherapy risk, trial design, and competition.

Read More